Abivax (LTS:0RA9) Net Change in Cash : €230.07 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Abivax Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Abivax's Net Change in Cash for the six months ended in Dec. 2024 was €0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was €230.07 Mil.

Abivax Net Change in Cash Historical Data

The historical data trend for Abivax's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax Net Change in Cash Chart

Abivax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

19.53

31.40

-33.75

224.99

-107.72

Abivax Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Dec24
Net Change in Cash	Get a 7-Day Free Trial															87.43	-121.18	-34.10	264.16	-

Abivax Net Change in Cash Calculation

Abivax's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-154.072	+	15.762	+	28.207	+	2.382
	=	-107.72

Abivax's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €230.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Abivax's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (LTS:0RA9) » Definitions » Net Change in Cash

Comparable Companies

XPAR:MEDCL XPAR:VLA XPAR:ALSEN XPAR:GNFT XPAR:IPH XPAR:NANO XPAR:OSE XPAR:ALCLS XPAR:IVA XPAR:TNG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270

Traded in Other Exchanges

ABVX:USA AAVXF:USA ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.

Abivax Headlines

No Headlines